Under the contract extension, Bayer will continue to supply Helixate FS to CSL Behring through 2017. At the same time, the companies settled outstanding litigation relating to the supply of Helixate FS. Terms of the settlement were not disclosed.
Under this agreement we will have the ability to increase the supply of Helixate available for our customers, said Peter Turner, president of CSL Behring.
This is also a collaboration that has served the global hemophilia community through expanded distribution of our reliable Kogenate and Helixate line of products, said Dr Gunnar Riemann, president of the pharmaceuticals division at Bayer HealthCare.
Helixate FS is a recombinant Factor VIII (FVIII) product used to treat hemophilia A when there is a demonstrated deficiency of FVIII, a plasma clotting factor.